CreatiVasc Medical

CreatiVasc Medical, founded in 2004, is a medical device company focused on developing solutions for end-stage renal disease (ESRD). The company was established in Greenville, South Carolina, by Dr. David Cull, a vascular surgeon who witnessed the challenges associated with traditional dialysis-access grafts firsthand. CreatiVasc began full-time operations in 2007.

The company's core product is the Hemoaccess Valve System®, a device designed to address the high rate of complications in dialysis patients. This system allows blood flow to a dialysis graft to be selectively activated during treatment and deactivated afterward, which helps in restoring normal circulation. The primary benefit is the potential reduction in clotting and graft failure, common issues with standard Teflon tube grafts which often lead to costly surgical interventions. Over 75% of traditional dialysis grafts are reported to fail within the first year. The Hemoaccess Valve System is implanted when the patient's access graft is created.

CreatiVasc operates in the medical device market, specifically targeting the ESRD patient population, a sector with significant healthcare costs in the U.S. The company's business model centers on the development and commercialization of its patented medical devices. In 2012, the U.S. Food and Drug Administration (FDA) selected CreatiVasc Medical as one of the first three companies for its Innovation Pathway program, a new initiative to accelerate the approval of breakthrough medical technologies. This selection highlighted the potential of the Hemoaccess Valve System to improve patient outcomes and reduce healthcare expenditures. The company has received funding from investors including the South Carolina Research Authority and a strategic investment of up to $5 million from Brookhaven Medical in 2013. CreatiVasc Medical was acquired by Brookhaven Medical on March 10, 2015.

Keywords: medical devices, end-stage renal disease, vascular access, dialysis, Hemoaccess Valve System, Dr. David Cull, graft failure, FDA Innovation Pathway, vascular surgery, medical technology, kidney failure, hemodialysis, arteriovenous graft, blood clotting, medical implants, surgical intervention, Brookhaven Medical, South Carolina Research Authority, chronic disease solutions, patient care improvement